Will Lar, Actually Adam Feuerstein (BOO!- Hiss!) suggested in an article
last year that Amgen consider acquiring AMRN. The reasoning being that
Amgen already is paying for a Cardiovascular Drug sales force, so why
put the sales reps to good use selling Vascepa. The price of Repatha
has already been cut substantially and now The Medicines Company has
a competing drug that will only have to injected twice a year instead
of twice a month. So Amgen would do quite well in acquiring AMRN as
it would be an excellent medication for them to sell in both the US
and in Europe. My own view is that a Mega-BP such as JNJ, NVS, Roche,
or MRK may be better contenders...but some smaller BP may be more
desperate for a Mega-Blockbuster product such as Vascepa. There
are many BP...but only one AMRN.
(Then again maybe a consortium of BP will end up owning AMRN.)
Market Data 
Markets 
AI
